Skip to main content
. 2016 Sep 28;44(1 Suppl):90–94. doi: 10.1177/0300060515593262

Figure 1.

Figure 1.

(a) Proportion of patients in remission assessed using various indices at 6 months, 1 year and 2 years after the start of treatment with antitumour necrosis factor (anti-TNF). (b) Proportion of patients with low disease activity (LDA) assessed using various indices at 6 months, 1 year and 2 years after the start of treatment with anti-TNF. (c) Number of patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and prednisone (PDN) before and during 2 years’ treatment with anti-TNF. CDAI, Clinical Disease Activity Index; SDAI, Simplified Disease Activity Index; DAS28, 28-joint Disease Activity Score.